Exiqon operates in two business areas: Life Sciences and Diagnostics. Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences.

Develops and manufactures drugs related to immunology, neurobiology and oncology

Beijing Jiyin Medical Technology Co., Ltd., established on 2021-12-20, Business scope includes technology development,Technical Services,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Natural science research and experimental development;Medical Research and Experimental Development;medical service.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Medical services and items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

SESVanderHave NV develops, produces and distributes sugar beet varieties. It engages in seed processing, production and research & development. The company was founded in 1879 and is headquartered in Tienen, Belgium.

MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom.

Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

Alnylam Europe AG, a subsidiary of Alnylam Pharmaceuticals, Inc., is a German company located in Munich involved in commercial physical and biological research. The firm was founded by Christian Angermayer. Alnylam Europe AG was acquired by Alnylam Pharmaceuticals, Inc. on July 07, 2003.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2018, the company has one approved drug (see the Products section below).

EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.

The business of Riboxx consists of two distinct product lines: LIFE SCIENCES and PHARMA. Riboxx LIFE SCIENCES develops customized and tailor-made molecular tools for gene silencing in vitro and in vivo through RNA interference: small interfering RNA (siRNA) and microRNA (miRNA). RNA interference is a new technology broadly used in life science. With the help of RNA interference, genotype-phenotype correlation studies as well as identification of gene expression patterns are possible. The core expertise of Riboxx LIFE SCIENCES is RNA synthesis and analytics. The direct applications of this technology are in the field of RNA interference, more precisely in vivo. Here, Riboxx has developed innovative molecular tools for gene silencing in vivo such as the IVORI® siRNA, the CONTRAmir® and CONmir®. The Riboxx RNAi-technology is robust, easy-to-use and reliable. Riboxx PHARMA has developed two families of TLR & RLR agonists with indications in the fields of oncology, virus infections and autoimmune disorders. The development pipeline at Riboxx comprises: - RIBOXXIM® compounds, for treatment of cancer or virus infections - RIBOXXON® compounds, for treatment of cancer and autoimmune diseases RIBOXXIM® and RIBOXXON® include more than 20 proprietary Active Pharmaceutical Ingredients (API) that possess unique properties as to potency, analytical purity, bioavailability, and safety.

AstraZeneca has always believed in science, inspires infinite possibilities, and puts science at the top of all work. AstraZeneca's strategically important core treatment areas, and are committed to exploring pathogenic mechanisms, treatment methods, and innovative drugs, so that science can change people's lives and bring it to the medical industry Significant changes.

Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. It operates through the following segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Therapeutics segment conducts research and development activities for therapeutic drug candidates. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Lakewood-Amedex is a biopharmaceutical company that focuses on developing novel-approach anti-infective products in the treatment of serious infectious diseases. The Company's products and technology are covered by an extensive patent portfolio consisting of 74 issued and 13 pending patents. It was founded in 2006 and headquartered in Sarasota, Florida.

Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Tianjin Biochip Technology Co., Ltd., established on 2003-09-26, The scope of business includes the development of biotechnology products,Production,processing,Sales and related technology transfer;Bioinformatics and Biotechnology Consulting,Serve.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Sirna Therapeutics, Inc. was a San Francisco, California based biotechnology company that explored the use of RNA interference in human disease therapy. Sirna's development pipeline includes several small interfering RNA (siRNA) drugs, thought to stably silence the expression of specific disease-related genes. Sirna's clinical trial of an siRNA-based treatment for age-related macular degeneration is the first such trial for an siRNA drug.